Masitinib
- Generic Name
- Masitinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H30N6OS
- CAS Number
- 790299-79-5
- Unique Ingredient Identifier
- M59NC4E26P
- Background
Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. It has been available in Europe since 2009, under the brand name Masivet. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
- Associated Conditions
- -
- Associated Therapies
- -
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- AB Science
- Target Recruit Count
- 200
- Registration Number
- NCT04622865
- Locations
- 🇫🇷
Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France
🇫🇷CHU Clermont-Ferrand: Site Gabriel-Montpied, Clermont-Ferrand, France
🇫🇷Le Tripode, Groupe hospitalier Pellegrin CHU de Bordeaux, Bordeaux, France
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- AB Science
- Target Recruit Count
- 140
- Registration Number
- NCT04333108
- Locations
- 🇫🇷
Hospital Jean-Minjoz, Besançon, France
🇫🇷Grenoble University Hospital, Grenoble, France
🇫🇷Hospital Claude Huriez, Lille, France
Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- AB Science
- Target Recruit Count
- 347
- Registration Number
- NCT03771040
- Locations
- 🇦🇷
Centro Respiratorio Quilmes, Buenos Aires, Argentina
🇲🇾Sarawak General Hospital, Kuching, Malaysia
🇵🇪Clínica Universidad de los Andes, Miraflores, Peru
Masitinib Plus Gemcitabine in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- AB Science
- Target Recruit Count
- 377
- Registration Number
- NCT03766295
- Locations
- 🇫🇷
Centre Hospitalier de Longjumeau, Longjumeau, France
🇬🇷General University Hospital of Patras, Patras, Greece
🇧🇪Hospital AZ Sint-Jan, Brugge, Belgium
Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- AB Science
- Target Recruit Count
- 714
- Registration Number
- NCT03761225
- Locations
- 🇮🇳
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
🇲🇾Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia
🇨🇦Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- AB Science
- Target Recruit Count
- 219
- Registration Number
- NCT03556956
- Locations
- 🇨🇿
University Hospital Olomouc, Olomouc, Czechia
🇫🇷Chu - Hopitaux de Rouen, Rouen, France
🇪🇸Hospital Madrid Norte San Chinarro, Madrid, Spain
Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- AB Science
- Target Recruit Count
- 248
- Registration Number
- NCT02490488
- Locations
- 🇩🇿
Centre hospitalo-universitaire de Beni Messous, Algiers, Algeria
🇷🇺City Oncology Clinic, St.-Petersburg, Russian Federation
🇫🇷Institut Sainte Catherine, Avignon, France
Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
- Conditions
- Interventions
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- AB Science
- Target Recruit Count
- 7
- Registration Number
- NCT02009423
Masitinib in Patients With Mild to Moderate Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- AB Science
- Target Recruit Count
- 721
- Registration Number
- NCT01872598
- Locations
- 🇵🇱
Centrum Zdrowia Stołeczna 7, Białystok, Poland
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain
🇬🇷General Hospital of Thessaloniki, Thessaloniki, Greece
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
- Conditions
- Interventions
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- AB Science
- Target Recruit Count
- 258
- Registration Number
- NCT01694277
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷Hôpital l'Archet 2- Service de Cancérologie Digestive, Nice, France
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.